Protease-activated receptor-2 involvement in hypotension in normal and endotoxemic rats in vivo

Citation
C. Cicala et al., Protease-activated receptor-2 involvement in hypotension in normal and endotoxemic rats in vivo, CIRCULATION, 99(19), 1999, pp. 2590-2597
Citations number
23
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
Journal title
CIRCULATION
ISSN journal
00097322 → ACNP
Volume
99
Issue
19
Year of publication
1999
Pages
2590 - 2597
Database
ISI
SICI code
0009-7322(19990518)99:19<2590:PRIIHI>2.0.ZU;2-U
Abstract
Background-The protease-activated receptor-2 (PAR-2) is expressed by vascul ar endothelial cells and upregulated by lipopolysaccharide (LPS) in vitro. PAR-2 is activated by a tethered ligand created after proteolytic cleavage by trypsin or experimentally by a synthetic agonist peptide (PAR-2AP) corre sponding to the new amino terminus of the tethered ligand. Methods and Results-Intravenous administration of PAR-2AP (0.1, 0.3, and 1 mg/kg) to rats: caused a dose-dependent hypotension. A scrambled peptide wa s without effect. A specific trypsin inhibitor, biotin-SGKR-chloromethylket one, inhibited trypsin-induced hypotension but not that stimulated by PAR-2 AP. In animals treated with LPS 20 hours earlier, we found an increased sen sitivity to trypsin and PAR-2AP in the hypotensive response. In particular, PAR-2AP caused hypotension at a low concentration of 30 ng/kg. Moreover, P AR-2 was immunolocalized to endothelial and smooth muscle cells in aorta an d jugular vein in LPS-treated rats, and increased levels of PAR-2 mRNA were shown by reverse transcription-polymerase chain reaction analysis. Conclusions-Our findings suggest that PAR-2 is important in the regulation of blood pressure in vivo. A functional upregulation of PAR-2 by LPS was de monstrated by the activity of concentrations of PAR-2AP that were inactive in normal animals. We conclude that PAR-2 may play an important role in the hypotension associated with endotoxic shock and may represent a new therap eutic target.